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NF-kB pathways in the development and progression of Colorectal Cancer 
M Patel, PG Horgan, DC McMillian and J Edwards 
Abstract 
NF-κB has been widely implicated in the development and progression of cancer. In colorectal 
cancer, NF-κB has a key role in cancer-related processes such as cell proliferation, apoptosis, 
angiogenesis and metastasis. The role of NF-κB in CRC is complex, owed to the crosstalk with other 
signalling pathways. Whilst there is sufficient evidence gained from cell lines and animal models that 
NF-κB is involved in cancer related processes, due to a lack of studies in human tissue, the clinical 
evidence of its importance is limited in patients with CRC. This review will summarise evidence 
relating to how NF-κB is involved in the development and progression of CRC and comment on 
future work to be carried out.  
Introduction 
Worldwide, colorectal cancer (CRC) is the third most common cause of cancer-related death (1). The 
majority of CRC cases are sporadic with a smaller proportion resulting as a consequence of 
inflammatory bowel disease (IBD) or inherited germ line mutations. The relationship between the NF-
κB pathway, inflammation and cancer has been widely reviewed (2–4). Much of the initial research 
linking NF-κB and CRC focused on chronic inflammation, was performed in mouse models of colitis 
and importantly demonstrated NF-κB functions are cell-type and tumour-type specific (5,6). Few 
reviews to date have evaluated the clinical significance of studies investigating NF-κB in CRC. NF-
κB activation supports tumourigenesis by enhancing cell proliferation and angiogenesis, inhibiting 
apoptosis and promoting cell invasion and metastasis (4). There are two distinct but interacting arms 
of the NF-κB pathway: canonical (activated by TNF-α, Toll-like receptor ligands e.g. 
lipopolysaccharide (LPS), and IL-1) and non-canonical (activated by TNF superfamily members 
BAFF, CD40, receptor-activated NF-κB ligand (RANKL) and lymphotoxin β) (7–12). NF-κB is a 
surrogate for a family of five related Rel proteins: RelA/p65, c-Rel, RelB, NF-κB1 (p50, p105 or 
p50/p105) or NF-κB 2 (p52, p100 or p52/100). p50 and p52 are produced by processing of precursors 
p105 and p100 respectively. These proteins have a common 300 amino acid Rel homology domain 
(RHD) (4) therefore once activated, their structural similarities allow formation of homo- and 
heterodimers, nuclear localisation, DNA binding and association with IκB inhibitors. In the latent cell 
IκB inhibitory proteins (IκBα, IκBβ, IκBε, IκBγ, IκBζ, p100 and p105) remain bound to the DD 
(dimerization domain) and NLS (nuclear localisation signal) of NF-κB proteins which are 
consequently rendered inactive within the cytoplasm (5–9). IκBs contain multiple copies of a 30-33 
amino acid sequence called ankyrin repeats which mediate their interaction with the RHD of NF-κB 
proteins, masking their NLS and thereby holding them bound inactive within the cytoplasm. Key 
steps in both arms of the pathway include activation by IκB kinase (IKK) complex resulting in the 
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phosphorylation-induced proteasomal degradation of IκB proteins, allowing dimers to form, enter the 
nucleus and bind to κB sites in promotor or enhancer regions of target genes (4,10). Each arm of the 
pathway has key roles in innate and adaptive immune responses, cell survival, cell death and 
inflammation (3).  
Sequential genetic mutations give rise to sporadic CRC through the adenoma-carcinoma sequence.  
Mutation of the adenomatous polyposis coli (APC) gene (and subsequent WNT activation and 
stabilisation of β-catenin) is recognised as one of the primary steps in colorectal adenoma formation. 
No activating mutations of NF-κB in CRC have been reported (3) however, constitutive activation of 
NF-κB has been observed (13–16) and is associated with higher tumour stage (15,17), treatment 
resistance (14,18–21) and poor survival outcomes (22).  As activation of NF-κB pathways have been 
associated with poor prognosis it is possible that members of the NF-κB pathways could be employed 
as prognostic markers or indeed novel therapeutic targets for CRC.   Importantly, the role of NF-κB in 
the transition of pre-malignant polyp to invasive carcinoma is unclear.  
The role of inflammation in CRC is undisputed and has been studied at the local tumour and systemic 
level. Within the field of CRC research there have been significant developments in understanding the 
role of the tumour microenvironment; stromal invasion and the local immune response are well 
recognised as important prognostic features (23,24). Consensus Molecular Subtypes and phenotypic 
subtypes of CRC have identified distinct groups of patients with strong immune activation, this has 
been associated with improved prognosis (25,26). Specifically, understanding the immune cell 
varieties and signalling pathways regulating them have resulted in development of prognostic 
biomarkers and subsequent introduction of immunotherapies in patients with metastatic disease. The 
addition of targeted immune therapies against EGFR (epidermal growth factor receptor), VEGFR 
(vascular endothelial growth factor receptor) and immune check points, to standard chemotherapy 
regimes, have led to improved survival in patients with metastatic CRC cancer, and have rendered 
some patients suitable for metastectomy with the potential for cure. NF-κB has key roles in a range of 
cancer-related processes and clearly presents itself as a potential prognostic biomarker and therapeutic 
target in CRC. This review will summarise evidence between 1995 and 2017 that reports on the 
relationship between NF-κB, colitis-associated however primarily sporadic CRC and how this 
signalling pathway influences the clinical development and progression of CRC.  
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Proliferation and evading apoptosis/antigrowth signalling 
Colorectal polys 
Polyps are recognised as precursors to CRC. They are classified into either adenomas or 
serrated/hyperplastic polyps, both with malignant potential. Vogelstein and colleagues have detailed 
the stepwise accumulation of molecular alterations that accompany the adenoma-carcinoma sequence 
(chromosomal instability pathway) which sees transformation through increasing grades of 
adenomatous dysplasia to the development of invasive carcinoma. (27). The role of NF-κB in 
adenoma formation in the context of colitis-associated cancer has been studied in mouse models that 
suggest NF-κB is implicated in the early stages of adenoma formation. However, there are no known 
studies that have mapped NF-κB expression in human tissue with respect to adenoma-carcinoma 
transformation. Nonetheless, a hybrid mouse model with intestinal epithelial cell-specific allelic 
deletion of APC and constitutive expression of IKKβ, displayed increase colonic adenoma formation 
than their APC allele deleted only counterpart. This study reported the hybrid model expressing IKKβ 
mostly increased adenoma number but did not increase the size of the adenoma suggesting IKKβ is 
implicated in adenoma initiation or early establishment (28). Serrated/hyperplastic polyps are 
considered as developing via distinct mechanism to that described by Vogelstein and it would be of 
interest to study NF-κB in this context.  If  confirmed in human studies NF-κB could be employed 
clinically identify which polyps have malignant potential.  
The anti-apoptotic activity of NF-κB is mediated via Bcl2, Bcl-xL, cFLIP, cIAP2, amongst other 
genes (4). Anti-apoptotic protein BAG-1 (Bcl-2-assocaited athanogene-1) is involved in key processes 
such as proliferation, cell signalling, transcription and apoptosis (29). Overexpression of BAG-1 has 
been reported in colorectal adenomas and carcinomas. The same study reported knockdown of BAG-1 
in colon cancer cell lines inhibited NF-κB transcriptional activity (30). A separate study reported this 
process is regulated by antigrowth protein/tumour suppressor Rb (retinoblastoma) (31). Inhibition of 
NF-κB with BAG-1 siRNA/inhibitor of NF-κB suppressed cell yield and induced apoptosis. This 
study concluded inhibition of NF-κB and therefore suppression of BAG-1 represents a novel 
therapeutic strategy in CRC (30).  
Colitis associated cancer 
The first genetic evidence linking canonical NF-κB activity, inflammation and CRC was from a 
mouse model of colitis-associated cancer where deletion of IKKβ in intestinal epithelial cells (IECs) 
and myeloid cells had distinct outcomes; deletion of IKKβ in IECs showed reduced adenoma 
incidence which was not related to levels of inflammation but had a direct effect on tumour 
promotion, as demonstrated by reduction in anti-apoptotic Bcl-2 protein, Bcl-xL. In contrast, deletion 
of IKKβ in myeloid cells was associated with a less marked reduction in adenoma incidence but was 
associated with reduced adenoma size, with reduced expression of genes encoding pro-inflammatory 
4 
 
cytokines such as IL-1β, IL-6 and TNFα, without no effect on apoptosis (5). These results suggest 
IKKβ mediated NF-κB activity has cell-specific roles in the development of colitis-associated cancer. 
Importantly, this study demonstrates the early role of NF-κB in the development of pre-cancerous 
adenomas which could be exploited clinically as a potential target. Therefore it is of interest to 
understand how NF-κB is implicated in the treatment of mouse models of colitis, IKKβ inhibitors 
have been observed to lead to smaller and less frequent tumour formation and may offer a novel mode 
of early intervention (33). 
When reviewed as a whole this evidence supports the hypothesis that there is a relationship between 
inflammation, NF-κB activity and tumourigenesis and indeed that NF-κB has a role in directly 
promoting tumourigenesis in colitis-associated cancer.   
Metastatic CRC 
The relationship between NF-κB and inflammation induced tumourigenesis was investigated in a 
metastatic colon cancer mouse model where it was observed that injection with bacterial LPS resulted 
in metastatic tumour growth via inflammatory mediator TNF-α. Intraperitoneal injection with colon 
cells transfected with mutant IκBα reduced tumour burden and improved murine survival. In vitro, 
this inhibition of NF-κB resulted in a cytocidal effect mediated by TRAIL (TNF-related apoptosis-
inducing ligand) (34). Observations from this study further support the link between NF-κB induced 
inflammation and growth of malignant cells in colon cancer. 
Human colon cancer stem cells have been identified (35,36) and can promote tumour formation and 
metastases in vivo (37,38). Signalling pathways implicated in this process include IL-6/STAT3 
(Signal Transduction Activator of Transcription-3) (37), activation of  AMPK/mTOR and NF-κB 
(38). In a genetic model with restricted WNT-activation, ablation of NF-κB (p65) restricted intestinal 
crypt stem cell expansion. Moreover, enhanced NF-κB activity increased Wnt activation and induced 
dedifferentiation of non-stem cells that acquire tumour-initiating capacity (39). Altogether, these 
studies support the role of NF-κB and indeed other closely linked signalling pathways such as STAT3 
in colon cancer stem cells implicated in tumourigenesis. Moreover, they highlight the need for further 
studies to investigate the effect of inhibiting NF-κB/STAT3 on tumour growth in the context of cancer 
stem cells to fully understand how these pathways could be exploited clinically as therapeutic targets.  
Evasion of apoptosis is a hallmark of a cancer. When proliferating cancer cells encounter hostile 
conditions e.g. hypoxia or insufficiency in nutrients, there are regulatory mechanisms which kick in. 
These include cell cycle arrest, apoptosis and autophagy. These processes are under the influence of 
tumour suppressor genes such as p53 (40). The p53 gene is mutated in 40-60% of CRCs (41). Whilst 
mutation of p53 is considered an important step in colorectal pathogenesis, studies investigating its 
prognostic and predictive capacity have reported conflicting results (42). However, the relationship 
between NF-κB and p53 and its importance in the development and progression of cancer is well 
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documented (43). A drug- and cytokine-induced p53/NF-κB crosstalk has been reported in colorectal 
cancer cells. Furthermore, TNF-α induced NF-κB target genes in colorectal cancer cells are dependent 
on this p53/NF-κB interaction (44). NF-κB is essential in p53-mediated cell death (45,46), mutant p53 
prolonged activation of NF-κB in cultured cells and was associated with increased susceptibility to 
colitis-associated CRC in vivo (47). 
Fibronectin is an extracellular glycoprotein which plays a role in cell adhesion, growth, migration, 
differentiation, inflammatory cell activity and tumour angiogenesis (48–51) and is highly expressed in 
CRC cell lines. Silencing of fibronectin increased apoptosis-related gene products caspase-3, p53, 
PARP, Bax and cytochrome c in vivo but decreased levels of NF-κB suggesting a relationship 
between fibronectin and the NF-κB/p53 signalling pathway (52), again providing evidence that NF-
κB plays a central role in regulating cell death in development and progression of CRC. Altogether, 
there is substantial evidence which shows NF-κB plays a diverse role in processes relating to 
proliferation, apoptosis and antigrowth signalling at all stages of CRC development i.e. from adenoma 
through to metastatic carcinoma and therefore offer exciting opportunities that could be exploited 
clinically. 
Angiogenesis 
Angiogenesis is a hallmark of cancer driven by VEGF (vascular endothelial growth factor). In 
addition to VEGF, CXCL1, CXCL8, IL-8 and COX-2 are also angiogenic regulators under the 
influence of NF-κB (53). Monoclonal antibodies against VEGF have been used to treat metastatic 
CRC for some time. VEGF is also inducible under hypoxic conditions by hypoxia-inducible factor 
(HIF). There are three HIF-α proteins: HIF-1α, HIF-2α and HIF-3α (regulator).The HIF pathway 
regulates cellular responses to hypoxia and also has a role in regulating inflammation and immune 
responses via cross-talk with NF-κB (54). The importance of this crosstalk was demonstrated by a 
group who confirmed HIF-1α inhibition by NF-κB inhibitor parthenolide which lead to 
downregulation of hypoxia-dependent angiogenesis in HUVECs (human umbilical vein endothelial 
cells), reduction in HIF-1α target gene proteins and inhibition of hypoxia induced epithelial-
mesenchymal transition (EMT). Furthermore, parthenolide treatment inhibited tumour growth, 
angiogenesis and progression in CRC xenograft models (55). Knock down of NEMO in CRC cell 
lines resulted in greater TNFα induced apoptosis and reduced expression of angiogenic factors IL-8, 
growth-regulated alpha protein (Groα) and monocyte chemoattractant protein 1 (MCP-1). In vivo, this 
knockdown resulted in reduced angiogenesis, tumour volumes, serum and tumour IL-8 expression and 
improved tumour regression when treated with fluorouracil (13,56). In CRC tissue, expression of NF-
κB (p65) associates directly with expression of HIF-1α, VEGF and histological evidence of vascular 
invasion (16,57). 
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These studies support the role of NF-κB, angiogenesis and tumour progression in CRC and highlight 
the importance of understanding crosstalk with other pathways to develop targeted therapies, 
particularly in those patients who may not respond to or experience toxicity with the available anti-
VEGF therapy. 
Metastasis and self-sufficiency in growth signals 
Unsurprisingly, NF-κB is involved in EMT of tumour cells. EMT results in epithelial cells acquiring 
the invasive and metastatic properties of mesenchymal cells and thus important in promoting cancer 
metastasis (58).  
Chemokines have been implicated in tumour metastases. Colon cells transfected with chemokine 
CXCL8 DNA displayed higher migration rate and EMT-like phenotype with increased expression of 
EMT markers N-cadherin, Vimentin and α-SMA as well as activation of PI3/Akt/NF-κB pathway. 
CXCL8 transfected mice displayed more rapid tumour growth compared to controls (59).   
Olfactomedins are a family of proteins which mediate development of the nervous system and 
haematopoiesis. Olfactomedin 4 (OLFM4) is an intestinal stem cell marker and a target of the Wnt/β-
catenin pathway. A recent study reported OLFM4 as a negative regulator of Wnt/β-catenin and NF-
κB pathways with inhibition of colon cancer development in APC mutated mice (60). Olfactomedin 1 
(OLFM1) also has a tumour suppressive role and is able to suppress growth, migration and invasion 
of CRC cells in vitro; Additionally, OLFM1 negatively regulated non-canonical NF-κB activity of 
NIK. Knockdown of OLFM1 promoted growth and metastasis of CRC cells in vivo; Low expression 
of OLFM1 in CRC tissue was associated with lymph node involvement, distant metastases and poor 
overall survival (61).  
Matrix Metalloproteinases (MMPs) are a family of proteolytic enzymes which have a physiological 
role of tissue remodelling and as such are able to degrade the extracellular matrix and facilitate 
tumour invasion. Overexpression of MMP 1, 2, 3, 7, 9 and 13 has been observed in human CRC (62) 
and were associated with poor prognosis and metastasis (63). The expression of MMP-9 is regulated 
by several transcription factors including NF-κB (64,65). The mechanistic link between NF-κB and 
MMP-9 was studied in CRC cells lacking the β subunit of the IKK complex and this showed NF-κB 
(IKK activity and p65) is required for TNF-α induced MMP-9 gene expression (66).  
NIK- and IKK-β-binding protein (NIBP) have been implicated in the regulation of cytokine-induced 
canonical NF-κB signalling. NIBP is over expressed in CRC tissue and is associated with metastasis 
(67,68). Nude mice injected with NIBP knockdown cells demonstrated less tumour formation, with no 
detectable tumour at 3 months (69). Expression of NIBP in 114 patient tissue samples of CRC was 
associated with tumour metastasis. The same study demonstrated NIBP overexpression induces 
activation of the canonical NF-κB pathway in vitro. Additionally, xenografts of NIBP-overexpressing 
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cells generated liver metastases with increased expression of p65, MMP-2 and MMP-9 suggesting 
NIBP may increase CRC metastases via canonical NF-κB activity and upregulation MMP-2 and 
MMP-9 (70). 
Cytoskeletal proteins Fascin and Ezrin have also been implicated in EMT and metastasis via NF-κB 
activity (71,72).  
Whilst the benefits of an adaptive immune response in the CRC tumour microenvironment has been 
widely demonstrated and now underpins therapeutic manipulation, the innate immune response is less 
understood. Specifically, the role of tumour-associated macrophages (TAMs) in CRC is controversial 
and the mechanisms behind phenotypical skewing towards either M1-like (pro-inflammatory/anti-
tumour Th1 response) or M2-like (anti-inflammatory/pro-tumour Th2 response) in CRC is 
incompletely understood (73).  In a study of knock in mice expressing a dominant negative form of 
IKK-α, treatment with carcinogen resulted in markedly reduced adenoma formation at 20 weeks, with 
smaller tumours and slower proliferation rates. This was associated with increased recruitment of M1 
(tumouricidal) -like myeloid cells into the tumour, which was not cell-autonomous but depended on 
interaction between mutant IKK-α epithelial and immune cells (74). In an interesting study using a 
model of peritoneal metastasis in immune-competent mice, intraperitoneal injection with IκBα-
suppressed colon cells induced an M1-like macrophage phenotype, with reduced liver and peritoneal 
metastases in vivo. This was associated with increased intratumoural activated CD4+ and CD8+ T cells 
and reduced angiogenesis (75). This study suggests targeting NF-κB could induce a phenotypic switch 
from M2-like immunosuppressive to an M1-anti-tumour macrophage in CRC. 
Activin A is a member of the TGFβ superfamily and has been reported to have a role in inflammatory 
responses (76). Activin A is overexpressed in human colorectal tumours, especially in stage IV 
disease suggesting activin A may have a role in advanced colorectal cancer (77). Signalling pathways 
for activin and TGFβ are frequently disrupted in CRC (78). Activin down regulates p21 and increases 
migration and invasion of colon cancer cells (79). The link between NF-κB signalling and activin 
ligand expression was investigated by the same group who reported activin, but not TGFβ, induced 
NF-κB activation with subsequent increased MDM2 ubiquitin ligase and degradation of p21 via PI3K 
dependent mechanism. Further to this, a functional role for NF-κB in activin-induced colon cancer 
cell migration was reported (80). 
Altogether, these findings further implicate NF-κB in important cancer processes such as EMT, 
autonomous growth signalling and regulation of the tumour microenvironment and how this might be 
manipulated as a therapeutic strategy. 
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NF-κB crosstalk with other signalling pathways  
There is evidence of cross talk between canonical and non-canonical NF-κB pathways (81,82), NF-κB 
and a number of other pathways, as well as studies demonstrating the ability of IKK kinases to 
directly target substrates in an NF-κB independent manner. The IKKs are regulated via their 
phosphorylation sites. Once phosphorylated, conformational change of the kinase results in activation. 
IKK-β is phosphorylated at serines 177 and 181(83,84). Crosstalk of IKK-β with Src kinase family is 
demonstrated by the c-Src dependent phosphorylation of Tyr188 and Tyr199 near the activation loop of 
IKK-β (85). IKK-α is phosphorylated at serines 176 and 180, autophosphorylation occurs at these 
sites when part of the IKK-β/NEMO complex. With respect to the non-canonical NF-κB pathway, 
NIK phosphorylates IKKα at serine 176 (86). Other proteins are also regulated via IKKα activation. 
For example, one mechanism of crosstalk between PI3K-Akt and NF-κB pathways is via 
phosphorylation of Thr23 on IKK-α (87). Both IKK-α and IKKβ have an NLS which renders them 
able to directly phosphorylate proteins at the nuclear level (12). For example, IKK-α has been 
implicated in the induction of NF-κB gene expression via phosphorylation of Ser 10 in Histone 3 (88). 
It would be of interest to study the role/expression of IKK phosphorylation sites in CRC. There has 
been little success in the development of IKK inhibitors and focused targeting of phosphorylation 
sites may offer an alternative therapeutic strategy.    
IL-1 can stimulate PI3K/Akt-dependent activation of NF-κB (p65), independent of the classical NF-
κB pathway (89,90). In non-colon cells, oncogenic Ras required P13K and Akt to stimulate NF-κB-
dependent transcription by targeting the transactivation domain of p65 rather than via classical 
degradation of IκB and subsequent translocation of p65 to the nucleus, with resulting reduced 
apoptosis (91). Loss of APC function and derangement of Wnt/β-catenin signalling have been firmly 
implicated in the development of CRC (92). It has been reported that IKK-α and IKKβ interacted with 
and were able to phosphorylate β-catenin, with IKK-α specifically able to increase β-catenin-
dependent gene expression in colon cancer cell lines (93). A separate study reported constitutive IKK-
β expression in mouse IEC induced spontaneous tumour formation, enhanced chemical- and APC 
mutation-mediated carcinogenesis and contrary to previous reports was associated with increased 
expression of β-catenin (94).  Furthermore, in human CRC tissue, it has been reported that 
PI3K/Akt/IKK-α pathway regulates NF-κB and β-catenin with the ability to influence transcription of 
genes implicated in angiogenesis and metastasis (95). When this evidence is considered as a whole it 
strongly supports the hypothesis that there is an interaction between the β-catenin, PI3/AKT and NF-
κB pathways in CRC development and progression. However, it is unclear whether IKKβ interacts 
with Wnt/B-catenin signalling in an NF-κB-dependent or independent fashion (96). 
The NF-κB and STAT3 interaction is important in orchestrating the immune and inflammatory 
response within the tumour microenvironment and each has distinct functions in immune and cancer 
cells (97). NF-κB and STAT3 regulate common processes and share regulatory binding sites of anti-
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apoptotic, cell cycle and proliferation, tissue resistance and repair genes, in addition to genes 
regulating angiogenesis/responses to hypoxia, chemokine and cytokine expression (98). As well as 
having distinct and overlapping target genes, as demonstrated by the pattern of their respective gene 
binding sites (99,100), NF-κB and STAT3 have been shown to physically interact (99,101) with 
STAT3 causing the nuclear retention of NF-κB; STAT3 can prolong nuclear retention of 
phosphorylated p65 (102). Co-localisation of STAT3 and NF-κB has been observed in CRC cell lines 
(103). MicroRNAs (miRNAs) function to suppress gene expression and have been reported to 
regulate NF-κB activity (104,105). In CRC cell lines transfected with microRNA mimics/inhibitors, 
miRNA-221 and miRNA-222 activated NF-κB (p65) and STAT3 with associated increase in miRNA-
221 and miRNA-222 suggesting these mRNAs function in a positive feedback regulatory loop to 
increase NF-κB and STAT3 activity. STAT3 activation is mediated by the tyrosine kinase JAK1 as a 
results of cytokine activity e.g. Interluekin-6 (IL-6). IL-6 is produced in an NF-κB dependent manner 
within myeloid cells in a model of colitis-associated cancer. The pro-tumourigenic effects of IL-6 
were mediated by STAT3 (106). STAT3 activity is found in epithelial and lymphocytic cells; 
inhibition of STAT3 in colon cancer cells curbs tumour cell proliferation in xenograft models of CRC 
(107). In CRC tissue, expression of STAT3 is associated with downregulation of the local adaptive 
immune response and decreased cancer-specific survival (108). No activating mutations in NF-κB or 
STAT3 have been detected in CRC suggesting they are secreted in a paracrine or autocrine fashion 
(109). 
Adaptive immunity is important in cancer immunosurveillance (110) and in CRC, the presence of 
tumour infiltrating immune cells (Th1 derivatives) have shown prognostic value independent of the 
widely used UICC-TNM classification (23). In contrast, high expression of T helper cell 17 (Th17)  
cells in CRC is associated with poor prognosis (111). There are a number of studies based on 
inflammation-associated colon cancer models that implicate inflammatory cell-derived cytokines (IL-
17A, IL-22, IL-6) to tumourigenesis (106,112,113). A study investigating the immune/inflammatory 
infiltrate and cytokine response in sporadic CRC found no differences in immune cell composition 
between uninvolved mucosa and tumour but did observe that this transition is marked by a functional 
switch in T cells leading to the accumulation of Th17-related cytokines, TNF-α and IL-6. 
Additionally, tumour-infiltrating lymphocyte-derived supernatant induced proliferation of colon 
cancer cell lines with activation and co-localisation of NF-κB and STAT3. These findings were 
confirmed in a mouse model of CRC. Interestingly, this study also observed that administration of a 
compound targeting STAT3/NF-κB activation and crosstalk, reduced levels of STAT3/NF-κB-
activating cytokines and tumour growth (103). This study highlights the importance of understanding 
the relationship between immune cell subtypes and cytokines and their influence on intracellular 
signalling pathways in sporadic CRC as well as highlighting STAT3/NF-κB crosstalk as a novel 
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therapeutic target in CRC. Moreover, it highlights a deficiency in studies of NF-κB in models of 
sporadic CRC.  
ERK5 and MEK5 overexpression has been reported in human adenomas and carcinomas and ERK5 
expression correlated with NF-κB. Colon cells with over activated ERK5 displayed increased NF-κB 
nuclear translocation and transcriptional activity; orthoptically implanted tumours with over activated 
MEK5/ERK5 had greater lymph node metastasis, altogether suggesting MEK5/ERK/NF-κB 
signalling is implicated in tumourigenesis and metastasis (114). 
As previously discussed the HIF pathway regulates cellular response to hypoxia and also have a role 
in regulating inflammation and immune responses via crosstalk with NF-κB. HIF and NF-κB share 
common activating stimuli, regulators and targets (54,115); Both HIF and NF-κB are activated in a 
TAK1-dependent manner (116) and IKK-β deficient mice demonstrate defective HIF expression and 
induction of target genes including vascular endothelial growth factor (VEGF) (115). High expression 
of HIF-2α in CRC tissue is associated with increasing tumour stage, poor tumour differentiation, 
lymphovascular invasion, COX-2 expression and worse overall survival (117).  
NF-κB independent roles of IKK-α  
The study of IKK-α in CRC has provided insights into its NF-κB independent functions and 
highlights it as an important player in colorectal carcinogenesis. Constitutive activation of IKK-α 
resulted in phosphorylation of SMRT at serine 2410 in CRC tissue. Furthermore, IKK-α binds to 
Notch-dependent gene promotors with resultant release of chromatin-bound SMRT and up-regulation 
of Notch-dependent gene and anti-apoptotic cIAP2 upregulation (118). Inhibition of IKK-α restored 
SMRT chromatin binding with inhibition of Notch-dependent gene transcription and subsequent 
reduction in tumour size in a CRC xenograft model (118). The same group have reported a truncated 
isoform of IKK-α with the predicted molecular weight of 45kda was generated by cathepsin mediated 
cleavage of full length IKK-α (FL-IKK-α) within early endosomes. Nuclear truncated IKK-α (p45-
IKK-α) forms a complex with full length IKK-α and NEMO and is responsible for regulating 
phosphorylation of SMRT and histone H3. This study provides evidence that p45-IKK-α results in 
diminished apoptosis in vitro and is required for CRC tumour growth in vivo (119). More recently, 
the same group demonstrated that KRAS and BRAF mutant (BRAFV600E) cells are different; whilst 
KRAS was able to induce canonical NF-κB signalling, BRAFV600E did not have the same effect. 
BRAFV600E is required for p45-IKK-α phosphorylation in a TAK1 dependent but NF-κB independent 
fashion. Additionally, endosomal inhibition reduced proliferation of BRAFV600E cells in culture as 
well as tumour growth and metastasis in xenograft models of CRC. The addition of an endosomal 
inhibitor appeared to potentiate the effect of Irinotecan in this model. FL-IKK-α, NEMO, TAK1 and 
BRAF were associated with the endosomal compartment however the nature of this association is 
unclear (120). 
11 
 
Whilst there is sufficient evidence gained from cell line and animal work relating to crosstalk between 
IKK-α and other signalling pathways in the development and progression of CRC, there is limited 
evidence that this is clinically important due to lack of studies investigating NF-κB in patient 
specimens and how this may relate to phenotypic tumour characteristics and patient outcomes.  
NF-κB and therapeutics 
In 2005, Gilmore and Hersovitch reported over 750 inhibitors of the NF-κB pathway including a 
variety of natural and synthetic molecules (121). 
COX-2 is a target gene of NF-κB (122) and is responsible for prostaglandin synthesis during 
inflammation. COX-2 is overexpressed in CRC (123), has been directly linked to colorectal 
tumourigenesis (124,125) and underpins the basis of numerous studies investigating the 
chemoprophylactic role of non-steroidal anti-inflammatory (NSAIDs) drugs such as aspirin and 
selective COX-2 inhibitors (126). The mechanism of COX-2 induction is not fully understood 
however it has been reported that in vitro inhibition of NF-κB can reduce COX-2 expression in 
colorectal cancer cells (127–129). Additionally, it has been reported that upregulation of COX-2 is 
associated with increased expression of p65, p50 and IKK-α in human colorectal cancer tissue, 
altogether suggesting a relationship between NF-κB signalling and COX-2 expression. 
Epidemiological data has demonstrated the protection conferred by Aspirin against CRC cancer (130). 
NF-κB plays a central role in anti-apoptotic NSAID activity in CRC cells in vitro (131–133). Both 
Aspirin and Sulindac inhibit IKK-β (131,134) and Aspirin, specifically, is able to induce 
phosphorylation and proteosomal-mediated degradation of IκBα and nuclear translocation of p65 
(133). Although Aspirin is known as an inhibitor of NF-κB, in xenograft models of human CRC, 
Aspirin increased levels of phosphorylated IκBα and nuclear p65 with associated apoptotic effect 
(135). These apoptotic effects were also reported in colon cells in vitro, independent of p53 or MMR 
status (136). It is evident that part of the chemoprophylactic nature of Aspirin in CRC can be 
attributed to NF-κB activity. 
Curcumin is a polyphenol derived from the spice turmeric and is active against a number of cell 
signalling pathways including NF-κB. In TNF stimulated cells treated with curcumin, onc study 
reported absence of NF-κB activity by inhibition of IκBα phosphorylation and translocation of p65 to 
the nucleus (137). In vitro, curcumin inhibited COX-2 by inhibition of NIK/IKK signalling and thus 
prevented phosphorylation of IκB in human colon cells (127). Curcumin has been and continues to be 
studied extensively. It has been reported to reduced colonic tumourigenesis in animal models 
(138,139) and to favour polarisation of macrophages toward an anti-tumour MI-like phenotype in 
xenograft models of colon cancer (139). NF-κB activity has been implicated in chemo- and radio-
resistance (18,19) and curcumin has been reported to overcome this by blocking NF-κB activity (20).  
The combination of curcumin and chemotherapeutic agent capecitabine effectively reduced tumour 
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volume, proliferation and microvessel density in vivo when compared to controls, with associated 
suppression of NF-κB-regulated gene products (21). In a separate study, curcumin was able to 
overcome oxaliplatin resistance via inhibition of NF-κB, in vitro (127). Later, the efficacious 
combination of curcumin and oxaliplatin was observed in xenograft models of CRC (140). The same 
group are currently investigating the combination of curcumin with FOLFOX chemotherapy within a 
phase II clinical trial of patients with metastatic CRC (141). 
For classical NF-κB activity, the proteasome plays an important role in degradation of IκB inhibitory 
protein. Proteosome inhibitor Bortezomib which is used to treat multiple myeloma has been 
investigated in CRC. Leucovorin is often given in combination with 5-fluorouracil (5-FU) to treat 
metastatic CRC. Treatment of CRC cells with leucovorin and Bortezomib enhanced caspase activity 
and apoptosis more effectively than either agent alone; these findings were confirmed in mouse CRC 
xenografts (142). Bortezomib has demonstrated limited efficacy in combination with standard 
treatment in clinical trials of patients with metastatic CRC (143,144). (See Table 1 for a summary of 
drugs targeting NF-κB that have clinical application in CRC). 
NF-κB activity interferes with the efficacy of chemotherapeutic agents through induction of anti-
apoptotic genes. There is no doubt that inhibiting IKK kinases suppresses CRC tumour growth in vivo 
as well as enhancing sensitivity to 5-FU (33,145,146). A number of IKK inhibitors have been reported 
in the literature but none have made it into clinical practice. Until now tools to unpick that exact 
nature of NF-κB inhibition have been limited due to the broad spectrum and non-specific nature of 
inhibitors.  However, it has now been reported that first in class IKK-α specific inhibitors are 
available (147). This should enable IKK-α as a novel therapeutic target to be explored and if validated 
might lead to translation into patients.  
NF-κB as a biomarker in CRC 
Activation of NF-κB has been observed in response to chemo- and radiotherapy (148–150). Much of 
the data relating to NF-κB as a predictor of treatment resistance in CRC is preclinical (151–156). In 
these studies aberrant NF-κB activity has been implicated in resistance to drugs used in the treatment 
of CRC such as 5-FU, oxaliplatin and irinotecan. Irinotecan is used in the treatment of metastatic 
CRC, many patients will develop eventual treatment resistance and disease progression which has 
been attributed to irinotecan-mediated NF-κB activation (155). The addition of an inhibitor of IKK-α 
to mouse xenograft models of colon cancer potentiated the antitumoural effect of irinotecan and 
increased the sensitivity of colon cells to 5-FU in vitro (146). Within a clinical trial of patients with 
irinotecan-refractory metastatic CRC treated with cetuximab and irinotecan, patients whose tumours 
expressed NF-κB (p65) had inferior response rates and overall survival compared to those patients 
whose tumours did not express NF-κB (18). This is one of the only clinical studies which has aimed to 
evaluate NF-κB in a predictive capacity.  
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Overexpression of p65 in CRC tissue was associated with increasing tumour stage (15,17) and poor 
overall survival (157). A study investigating the prognostic significance of NF-κB, HIF-1α and VEGF 
expression in 148 patients who had undergone potentially curative resection for stage III CRC found 
that NF-κB expression was an independent predictor of overall survival. Additionally, the 56 patients 
who relapsed had inferior response rates (and overall survival) to palliative chemotherapy.  
Patients with metastatic CRC undergo testing to determine KRAS status; this practice is widely 
established and harbouring the KRAS mutation precludes treatment with anti-epidermal growth factor 
(EGFR) receptor monoclonal antibody. NF-κB can be activated through RAS-RAF signalling 
pathway. Expression of oncogenic KRAS has been reported to result in NF-κB activation (158–160). 
Knockdown of KRAS reduces expression of p65 and phosphorylated-IκBα in CRC cell lines (161). 
Studies have reported higher expression of NF-κB (p65) in CRC tissue of patients with KRAS 
mutation than those without.  NF-κB activation in the presence of KRAS mutation was associated 
with inferior overall survival in stage I-IV disease and reduced response to chemotherapy in patients 
with metastatic disease (162). However, in a study of patients with KRAS wild-type metastatic CRC 
treated with irinotecan and cetuximab, 65% had tumours expressing p65 and this was associated with 
poorer progression-free and overall survival than those patients with NF-κB negative tumours, 
suggesting NF-κB expression is prognostic irrespective of KRAS mutational status. 
A study of 22 patients investigating the relationship between radiotherapy for rectal cancer, NF-κB 
activation and treatment response reported that NF-κB target genes are upregulated in response to a 
single fraction of radiotherapy however, whilst expression of NF-κB subunit p50 was prognostic for 
overall survival, it was not predictive of pathological response to radiotherapy.  
  
Concluding remarks 
This review summarises evidence from pre-clinical, translational and clinical studies that have 
reported on NF-κB with respect to the development and progression of CRC. There is substantial 
evidence implicating NF-κB in all stages of CRC development, from early adenoma to invasive 
cancer and metastasis. The role of NF-κB in CRC is undoubtedly complex and this complexity is 
enhanced by the crosstalk of NF-κB with a multitude of signalling pathways and regulators. 
Therefore, together with its essential role in normal cellular physiology it is unsurprising that 
inhibitors of NF-κB have yet to successfully emerge into clinical practice. 
There is a growing body of evidence from studies in cell lines and animals implicating NF-κB activity 
in the development, progression and treatment resistance of CRC. Many studies focus on the 
measurement of p65 activity/expression as a measure of NF-κB activity which largely reflects the 
canonical pathway. Future studies should pursue investigation of non-canonical NF-κB activity which 
14 
 
appears to be underexplored. Importantly, there is a lack of studies in human tissue and therefore in 
understanding the relationship between NF-κB and phenotypic tumour characteristics. It would also 
be prudent to understand the role of NF-κB activity in the development of pre-malignant polyps and 
their transformation into invasive cancers. Finally, molecular and phenotypic subtypes of CRC have 
been proposed (25,26) and the study of NF-κB in the context of these subtypes would help to further 
decipher the biology of CRC.  
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Name of 
drug/molecule 
Type of 
molecule i.e. 
natural 
product, 
synthetic, 
protein 
Point of activity References Stage of 
development/Clinical 
application 
Aspirin, sodium 
salicylate 
Synthetic  IκBα 
phosphorylation, 
IKKβ inhibition 
Kopp & Ghosh, 
1994 [1]; 
Yin et al. 1998 [2] 
Stark et al. 2005 
[3] 
Epidemiological evidence 
of reduced rick of 
colorectal adenomas with 
regular aspirin use[4–7]. 
Use of daily aspirin was 
associated with reduction 
in incidence of colorectal 
adenomas in patients with 
history of adenomas or 
previous colorectal cancer 
[8].   
There are a number of 
active clinical trials aimed 
at determining the risk-
benefit profile of Aspirin 
as a chemopreventive 
agent. 
Selective COX-2 
inhibitors e.g. 
Celecoxib, Rofecoxib 
Synthetic COX- dependent and 
independent activity  
Grösch et al., 2006 
[9] 
Three large double blind 
randomised controlled 
trials showed COX-2 
inhibitors prevent 
recurrence of sporadic 
adenomas with an 
increased cardiovascular 
risk [10–12]. Currently not 
routinely used as a 
preventative or therapeutic 
option in CRC. 
Curcumin 
(Diferulolylmethane) 
Natural 
antioxidant 
NIK/IKK signalling 
 
IκBα 
phosphorylation, 
translocation of p65 
Plummer et al., 
1999 [13] 
Singh and 
Aggarwal, 1995 
[14] 
Phase I/II clinical trial of 
combination FOLFOX and 
curcumin in patients with 
metastatic colorectal 
cancer with inoperable 
liver metastases has 
completed recruitment 
phase – results awaited 
[15]. 
Bortezomib Synthetic Proteasome Adams & Limited efficacy of 
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Kauffman, 2004 
[16] 
Bortezomib in 
combination with standard 
treatment in phase I/II 
clinical trials of patients 
with metastatic CRC 
[17,18]. 
     
 
 
    
 
 
 
